Showing results (61-70 of 83) with videos related to
Sort By:
Pageof 9
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.Journal of Hematology & Oncology|May 1, 2013
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Reinhard Stauder, Sonja Burgstaller, et al.European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study groupThomas Melchardt, Teresa Magnes, Clemens Hufnagl, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 24, 2021
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathyStefan Hatzl, Florian Posch, Arwin Rezai, et al.Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.Haematologica|February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysisHishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.Transplantation and Cellular Therapy|April 19, 2026
Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphomaStefan Koeck, Natalia Rotter, Olga Stiefel, et al.Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.Pageof 9